PubMed · 17199031
Retigabine.
Abstract
Retigabine is a novel antiseizure drug that acts through potassium channels and has activity in a broad range of animal models of epilepsy. It is also effective in several preclinical pain models. The drug has been extensively studied in phase I and II studies, with very promising results. The maximal tolerated dose for most patients is 1,200 mg/day. Adverse effects have been largely CNS-related and mild; most have occurred during the titration periods in the various studies. At present, retigabine is in two pivotal phase III studies.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Roger J Porter, Virinder Nohria, Chris Rundfeldt. 2007. Retigabine.. https://doi.org/10.1016/j.nurt.2006.11.012
Cite the original work for its findings. Save a collection to share your selection of sources.